EXPERIENCE OF ABATACEPT TREATMENT IN A PATIENT WITH SEROPOSITIVE POLYARTHRITIS FROM RISK GROUP OF TUBERCULOSIS INFECTION
https://doi.org/10.15690/vsp.v12i6.888
Abstract
A short review on modern views on abatacept usage in treatment of juvenile idiopathic arthritis is shown in this article with highlighting of the high safety of this drug in accordance with severe opportunistic infections, including tuberculosis. The authors also discuss possibility of its usage in cases of inefficiency (intolerability) of tumor necrosis factor alpha in combination with methotrexate or as monotherapy. A history case of abatacept treatment of polyarticular type of juvenile idiopathic arthritis with risk factors of unfavorable outcome, severe associated disease and latent tuberculosis infection is demonstrated.
About the Authors
L. A. Balykova
Medical Institute of Mordovian State University named after N.P. Ogarev, Saransk
Russian Federation
Balykova Larisa Aleksandrovna, Doctor of Medical Science, Professor, Head of the Department of Pediatrics
Russian Federation
Balykova Larisa Aleksandrovna, Doctor of Medical Science, Professor, Head of the Department of Pediatrics
N. V. Shchekina
Mordivian Pediatric Republican Clinical Hospital №2, Saransk
Russian Federation
Russian Federation
A. V. Krasnopol’skaya
Medical Institute of Mordovian State University named after N.P. Ogarev, Saransk
Russian Federation
Russian Federation
T. I. Kornilova
Mordivian Pediatric Republican Clinical Hospital №2, Saransk
Russian Federation
Russian Federation
N. A. Os'kina
Medical Institute of Mordovian State University named after N.P. Ogarev, Saransk
Russian Federation
Russian Federation
References
1. Beukelman T., Patkar N. M., Saag K. G., Tolleson-Rinehart S., Cron R. Q., DeWitt E. M., Ilowite N. T., Kimura Y., Laxer R. M., Lovell D. J., Martini A., Rabinovich C. E., Ruperto N. 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Res. (Hoboken). 2011; 63: 1355–1356.
2. Baranov A. A., Alekseeva E. I., Bzarova T. M., Valieva S. I., Denisova R.V., Isaeva K.B., Karagulyan N.A., Litvitskii P.F., Mitenko E.V., Sleptsova T. V., Fetisova A.N., Chistyakova E.G., Taibulatov N. I., Morev S.Yu. Voprosy sovremennoy pediatrii — Current Pediatrics. 2013; 1: 37–56.
3. Choy E. H., Panayi G. S. Cytokine pathways and joint inflammation in rheumatoid arthriti. New Engl. J. Med. 2001; 344: 907–916.
4. Hervey P. S., Keam S. J. Abatacept. BioDrugs. 2006; 20 (1): 53–61. 5. Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.
5. Kremer J. M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52 (8): 2263–2271.
6. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford). 2011; 50 (3): 437–449.
7. Salliot C., Finckh A., Katchamart W., Lu Y., Sun Y., Bombardier C., Keystone E. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumor necrosis factor agents: a meta-analysis. Ann. Rheum. Dis. 2011; 70: 266–271.
8. Schoels M., Aletaha D., Smolen J. S., Wong J. B. Comparative effectiveness and safety of biological treatment options after tumor necrosis factor inhibotor failure in rheumatoid arthritis: systemic review and indirect pairwise meta-analysis. Ann. Rheum. Dis. 2012.
9. Ruderman E. M. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012; 51: 37–43.
10. Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann. Rheum. Dis. 2009; 68: 25–32.
11. Ruperto N., Lovell D. J., Quartier P., Paz E., Rubio-Perez N., Silva C. A. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, doubleblind, placebo-controlled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.
12. Durmoqicz E. L. Pediatric focused safety review. FDA [online]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ ucm193143.pdf. Accessed 2010 Dec 21.
13. Alekseeva E. I., Valieva S. I., Bzarova T. M., Denisova R. V., Isaeva K. B., Sleptsova T. V., Mitenko E. V., Taybulatov K. I. Rezultaty otkrytogo klinicheskogo issledovaniya IV fazy po izucheniyu effektivnosti i bezopasnosti abatatsepta u detey i podrostkov s poliartikulyarnym yuvenilnym idiopaticheskim artritom bez sistemnykh proyavleniy v Rossii [Results of an open clinical phase IV trial on determining the effectiveness and safety of abatacept in children and adolescents with polyarticular juvenile idiopathic arthritis without systemic manifestations in Russia]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2013; 12 (4): 64–72.
14. Khraishi M., Russell A., Olszynski W. P. Safety profile of abatacept in rheumatoid arthritis: A review. Clin. Ther. 2010; 32: 1855–1870.
15. Weinblatt M. E., Moreland L. W., Westhovens R. et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J. Rheumatol. 2013; 40: 787–797.
16. Tran T. N., Caspard H., Magrini F. Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis — a systematic evaluation of the literature. Open Access Rheumatology: Research and Reviews. 2013; 5: 21–32.
17. Flynn J. L., Goldstein M. M., Chan J. et al. Tumor necrosis factoralpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995; 2: 561–572.
18. Dixon W. G., Hyrich K. L., Watson K. D., Lunt M., Galloway J., Ustianowski A. et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann. Rheum. Dis. 2010; 69: 522–528.
19. Bigbee C. L., Gonchoroff D. G., Vratsanos G. et al. Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum. 2007; 56: 2557–2565.
Review
For citations:
Balykova L.A., Shchekina N.V., Krasnopol’skaya A.V., Kornilova T.I., Os'kina N.A. EXPERIENCE OF ABATACEPT TREATMENT IN A PATIENT WITH SEROPOSITIVE POLYARTHRITIS FROM RISK GROUP OF TUBERCULOSIS INFECTION. Current Pediatrics. 2013;12(6):130-135. (In Russ.) https://doi.org/10.15690/vsp.v12i6.888
Views:
741
Email this article 
